US 11,786,554 B2
Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene
James Jefferson Smith, Morrisville, NC (US); Janel Lape, Wake Forest, NC (US); Hui Li, Apex, NC (US); and Jochen Genschel, Raleigh, NC (US)
Assigned to Precision BioSciences, Inc., Durham, NC (US)
Appl. No. 17/46,761
Filed by Precision BioSciences, Inc., Durham, NC (US)
PCT Filed Apr. 11, 2019, PCT No. PCT/US2019/027019
§ 371(c)(1), (2) Date Oct. 9, 2020,
PCT Pub. No. WO2019/200122, PCT Pub. Date Oct. 17, 2019.
Claims priority of provisional application 62/656,809, filed on Apr. 12, 2018.
Prior Publication US 2021/0113616 A1, Apr. 22, 2021
Int. Cl. C12N 9/22 (2006.01); C12N 15/86 (2006.01); A61K 35/17 (2015.01); C07K 14/725 (2006.01)
CPC A61K 35/17 (2013.01) [C07K 14/7051 (2013.01); C12N 9/22 (2013.01); C12N 15/86 (2013.01); C12N 2750/14143 (2013.01)] 5 Claims
OG exemplary drawing
 
1. An engineered meganuclease that binds and cleaves a recognition sequence consisting of SEQ ID NO: 5 within a human T cell receptor (TCR) alpha constant region gene, wherein said engineered meganuclease comprises an amino acid sequence of SEQ ID NO: 7.